Efficacy of peg-interferon-α-2a plus ribavirin for patients aged 60 years and older with chronic hepatitis C in Korea.

摘要: Background and Aim:  In the present study, we evaluated safety efficacy of combination therapy with pegylated interferon ribavirin for treating chronic hepatitis C (CHC) patients aged 60 years older. Methods:  A total 314 CHC patients, who were treated therapy, classified into three groups according to age: (i) younger than 50 years (n = 137); (ii) 50–59 years (n = 109); (iii) or older (n = 68). The sustained virological response (SVR) discontinuation rates compared between groups. Results:  Discontinuation due adverse event was more frequent in patient groups: 1%, 5%, 10% < 50-year, 50–59-year, ≥ 60-year groups, respectively (P = 0.018). However, showed a SVR rate that comparable other age 80%, 73%, 75% ≥ 60-year- (P = 0.420). multivariate analysis aspartate aminotransferase : platelet ratio index (APRI) an independent predictor SVR. An achieved 95% (19/20) elderly APRI < 0.80. Conclusions:  Although physicians must pay attention events can be considered especially low APRI.